NK

Naseer Kannu Abdul Asees

Director Director DIN 09106160
DIN 09106160 First appointment Mar 2021 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since Mar 2021
Shareholding value •••• Premium profile

About Naseer Kannu Abdul Asees

Data last updated:

Naseer Kannu Abdul Asees was a Director at Aimed Pharma Private Limited (2022–2023) and Director at Eimer Pharma Private Limited (2021–2023). The companies operate in Chemicals and Pharma.

DIN 09106160
Primary Designation Director
Industry Chemicals
First Appointment 15 Mar 2021

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Aimed Pharma Private Limited U24230KA2022PTC168512
Director01 Dec 20222022Active
Eimer Pharma Private Limited U52311KL2021PTC068029
Director15 Mar 20212021Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Aimed Pharma Private Limited
Eimer Pharma Private Limited
Premium access

Shareholding and investment profile for Naseer Kannu Abdul Asees

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Naseer Kannu Abdul Asees

Naseer Kannu Abdul Asees was first appointed on 15 Mar 2021 as Director at Eimer Pharma Private Limited. The most recent appointment on record is 01 Dec 2022 at Aimed Pharma Private Limited.

Naseer Kannu Abdul Asees held 2 earlier board appointments: Aimed Pharma Private Limited (Director, 01 Dec 2022 to 07 Jun 2023); Eimer Pharma Private Limited (Director, 15 Mar 2021 to 30 May 2023).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available